CAJ | 학술논문

目的：观察奥替溴铵联合草酸艾司西酞普兰治疗肠易激综合征（IBS）的疗效。方法：按罗马Ⅲ诊断标准选择60例肠易激综合征患者，按就诊顺序奇偶数分组，奇数为研究组，偶数为对照组，各30例。入组前均进行肠易激综合征症状严重程度量表（IBS-SSS）评分，入组后12周内两组均给予奥替溴铵40 mg，tid，研究组联用草酸艾司西酞普兰10 mg/d；12周后，研究组继续服用草酸艾司西酞普兰至24周，两组在12~24周期间均根据腹痛情况按需服用奥替溴铵（不作常规服用）。分别在治疗2、4、8、12、24周末各评定一次治疗效果。结果：治疗第2、4、8、12、24周末研究组IBS-SSS评分依次为（185.00±38.24）分、（149.07±38.30）分、（127.83±37.51）分、（112.97±37.55）分、（102.97±43.82）分，对照组评分依次为（226.80±42.98）分、（183.33±41.90）分、（165.33±37.19）分、（152.30±39.41）分、（147.57±41.46）分，两组比较差异均有统计学意义（P<0.01）。结论：联合使用草酸艾司西酞普兰和奥替溴铵更能缓解患者的腹痛、腹部不适症状及排便异常现象，并能提高患者的生活质量，疗效持久，安全耐受性好，持续用药复发风险小。
목적：관찰오체추안연합초산애사서태보란치료장역격종합정（IBS）적료효。방법：안라마Ⅲ진단표준선택60례장역격종합정환자，안취진순서기우수분조，기수위연구조，우수위대조조，각30례。입조전균진행장역격종합정증상엄중정도량표（IBS-SSS）평분，입조후12주내량조균급여오체추안40 mg，tid，연구조련용초산애사서태보란10 mg/d；12주후，연구조계속복용초산애사서태보란지24주，량조재12~24주기간균근거복통정황안수복용오체추안（불작상규복용）。분별재치료2、4、8、12、24주말각평정일차치료효과。결과：치료제2、4、8、12、24주말연구조IBS-SSS평분의차위（185.00±38.24）분、（149.07±38.30）분、（127.83±37.51）분、（112.97±37.55）분、（102.97±43.82）분，대조조평분의차위（226.80±42.98）분、（183.33±41.90）분、（165.33±37.19）분、（152.30±39.41）분、（147.57±41.46）분，량조비교차이균유통계학의의（P<0.01）。결론：연합사용초산애사서태보란화오체추안경능완해환자적복통、복부불괄증상급배편이상현상，병능제고환자적생활질량，료효지구，안전내수성호，지속용약복발풍험소。
Objective: To observe the effect of Otilonium bromide combined with Oxalic acid Ai Sciplan in the treatment of irritable bowel syndrome (IBS).Method: 60 cases with irritable bowel syndrome were selected according to the Rome Ⅲ diagnosis criteria, they were grouped by the visit order of odd and even, odd as the research group, even for the control group, 30 cases in each group. Before entering the group ,they were score by irritable bowel syndrome severity scale (IBS-SSS), when enrolled the two groups were given otilonium bromide 40 mg,tid, the research group in conjunction with oxalic acid Ai Sciplan 10 mg/d within 12 weeks. After 12 weeks, the research group continues taking escitalopram oxalate to 24 weeks, the two groups used otilonium bromide according to abdominal pain duringon-demand during 12 to 24 weeks (not as a conventional take).Result: The treatment effect was evaluated respectively at the end of 2, 4, 8, 12, 24 weeks, and the IBS-SSS scores of the research group were (185.00±38.24), (149.07±38.30), (127.83±37.51), (112.97±37.55), (102.97±43.82), the control group scores were (226.80±42.98), (183.33±41.90), (165.33±37.19), (152.30±39.41), (147.57±41.46), followed by the two groups, the control group scores were significantly different (P<0.01).Conclusion: Joint use of escitalopram oxalate and otilonium bromide can ease patients abdominal pain, abdominal discomfort and abnormal bowel movements, improve the quality of life of patients at the same time. This method has lasting efficacy, safety, well tolerated, and small relapse risk when sustained drug use.